Humoral hypercalcemic factor antagonists modified at position 13 by biotin
US5087561A · kind A · utility
3Cited by
2References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 28, 1990 |
| Grant date | Feb 11, 1992 |
| Priority date | — |
| Expiry date | Jun 28, 2010 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/29
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human humoral hypercalcemic factor (hHCF), wherein Lys.sup.13 or Lys.sup.11 is modified on the epsilon-amino group by biotin so as to produce HCF analogues which can inhibit the action of HCF.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.